托法替尼（CP-690550）导致结核分枝杆菌再激活的风险。
Risk of tuberculosis reactivation with tofacitinib (CP-690550).
机构信息
Center for Tuberculosis Research, Johns Hopkins School of Medicine, Baltimore, MD, USA.
出版信息
J Infect Dis. 2012 Jun;205(11):1705-8. doi: 10.1093/infdis/jis269. Epub 2012 Apr 3.
Abstract
Individuals with latent tuberculosis infection (LTBI) live with a risk of reactivation, and several treatments for chronic inflammatory conditions are highly associated with such reactivation. A new Janus kinase inhibitor, tofacitinib (CP-690550), has shown promising results for treatment of inflammatory disorders, thus raising concerns of risk of active tuberculosis. Our goal was to characterize the impact of tofacitinib on LTBI using a mouse model of contained tuberculosis. Our data indicate that tofacitinib reduces host containment of Mycobacterium tuberculosis and promotes bacterial replication in the lungs, suggesting tuberculosis reactivation. Tofacitinib may carry a significant risk for LTBI reactivation in humans.
摘要
潜伏性结核感染（LTBI）个体存在再激活的风险，而几种慢性炎症性疾病的治疗方法与这种再激活高度相关。一种新型的 Janus 激酶抑制剂托法替尼（CP-690550）已显示出对治疗炎症性疾病有良好的效果，因此引起了对活动性结核的风险的担忧。我们的目标是使用包含性结核的小鼠模型来描述托法替尼对 LTBI 的影响。我们的数据表明，托法替尼降低了宿主对结核分枝杆菌的控制，并促进了肺部细菌的复制，提示结核再激活。托法替尼可能会对人类 LTBI 的再激活带来重大风险。
相似文献
1
Risk of tuberculosis reactivation with tofacitinib (CP-690550).托法替尼（CP-690550）导致结核分枝杆菌再激活的风险。
J Infect Dis. 2012 Jun;205(11):1705-8. doi: 10.1093/infdis/jis269. Epub 2012 Apr 3.
2
Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions.在应激条件下，口服Janus激酶抑制剂托法替布而非奥克拉替尼会诱发攻击行为。
Eur J Pharmacol. 2015 Oct 5;764:278-282. doi: 10.1016/j.ejphar.2015.06.060. Epub 2015 Jul 9.
3
Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies.生物制剂和托法替尼治疗慢性免疫介导的炎症性疾病患者的结核病风险：随机对照试验和长期扩展研究的系统评价和荟萃分析。
Rheumatology (Oxford). 2014 Oct;53(10):1872-85. doi: 10.1093/rheumatology/keu172. Epub 2014 May 11.
4
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.托法替布治疗的类风湿关节炎患者中的结核病及其他机会性感染。
Ann Rheum Dis. 2016 Jun;75(6):1133-8. doi: 10.1136/annrheumdis-2015-207319. Epub 2015 Aug 28.
5
Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis.辅助托法替尼治疗结核分枝杆菌感染的小鼠模型的疗效。
EBioMedicine. 2015 Jul 14;2(8):868-73. doi: 10.1016/j.ebiom.2015.07.014. eCollection 2015 Aug.
6
A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis.一项关于托法替尼（CP-690550）治疗类风湿关节炎的新型口服药物真菌感染风险的研究。
Sci Rep. 2017 Jul 28;7(1):6779. doi: 10.1038/s41598-017-07261-1.
7
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.托法替布治疗类风湿关节炎长达8.5年的长期安全性：来自全球临床试验数据的综合分析
Ann Rheum Dis. 2017 Jul;76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31.
8
Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis.类风湿关节炎患者接受托法替布治疗后的结核病、乙型肝炎和带状疱疹。
Immunotherapy. 2019 Mar;11(4):321-333. doi: 10.2217/imt-2018-0113. Epub 2019 Jan 11.
9
Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.托法替布（CP-690,550），一种口服的Janus激酶抑制剂，在一项针对中重度银屑病患者的2b期随机双盲安慰剂对照研究中改善了患者报告的结局。
J Eur Acad Dermatol Venereol. 2014 Feb;28(2):192-203. doi: 10.1111/jdv.12081. Epub 2013 Jan 7.
10
Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.在中重度溃疡性结肠炎中评估托法替布疗效的暴露-反应特征：一项剂量范围的 2 期试验结果。
Br J Clin Pharmacol. 2018 Jun;84(6):1136-1145. doi: 10.1111/bcp.13523. Epub 2018 Mar 23.
引用本文的文献
1
Isolated splenic tuberculosis in a patient with rheumatoid arthritis.一名类风湿关节炎患者的孤立性脾结核。
IDCases. 2025 Jun 19;41:e02295. doi: 10.1016/j.idcr.2025.e02295. eCollection 2025.
2
Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents.接受生物技术和靶向免疫抑制剂治疗的慢性自身免疫性关节炎患者的结核病风险管理、筛查及预防性治疗
Front Immunol. 2025 Feb 3;16:1494283. doi: 10.3389/fimmu.2025.1494283. eCollection 2025.
3
Applications of Biological Therapy for Latent Infections: Benefits and Risks.生物疗法在潜伏感染中的应用：益处与风险。
Int J Mol Sci. 2024 Aug 24;25(17):9184. doi: 10.3390/ijms25179184.
4
Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis: post-marketing surveillance study.托法替布治疗韩国成年溃疡性结肠炎患者的安全性和有效性：上市后监测研究。
BMC Gastroenterol. 2024 Aug 19;24(1):273. doi: 10.1186/s12876-024-03336-2.
5
Tofacitinib use in ulcerative colitis: An expert consensus for day-to-day clinical practice.托法替布在溃疡性结肠炎中的应用：日常临床实践专家共识
Indian J Gastroenterol. 2024 Feb;43(1):22-35. doi: 10.1007/s12664-023-01507-9. Epub 2024 Feb 12.
6
The Saudi consensus recommendations for the management of psoriatic arthritis (2023).沙特阿拉伯银屑病关节炎管理共识建议（2023 年）。
Clin Rheumatol. 2024 Mar;43(3):879-894. doi: 10.1007/s10067-024-06867-x. Epub 2024 Jan 13.
7
Tofacitinib treatment of rheumatoid arthritis increases senescent T cell frequency in patients and limits T cell function in vitro.托法替尼治疗类风湿关节炎增加患者衰老 T 细胞频率并限制体外 T 细胞功能。
Eur J Immunol. 2023 Aug;53(8):e2250353. doi: 10.1002/eji.202250353. Epub 2023 May 31.
8
Host-directed immunotherapy of viral and bacterial infections: past, present and future.靶向宿主免疫疗法治疗病毒和细菌感染：过去、现在和未来。
Nat Rev Immunol. 2023 Feb;23(2):121-133. doi: 10.1038/s41577-022-00734-z. Epub 2022 Jun 7.
9
Risk of Tuberculosis Development in Patients with Rheumatoid Arthritis Receiving Targeted Therapy: a Prospective Single Center Cohort Study.类风湿关节炎患者接受靶向治疗后发生结核病的风险：一项前瞻性单中心队列研究。
J Korean Med Sci. 2021 Mar 15;36(10):e70. doi: 10.3346/jkms.2021.36.e70.
10
Host-directed therapies for bacterial and viral infections.宿主导向疗法治疗细菌和病毒感染。
Nat Rev Drug Discov. 2018 Jan;17(1):35-56. doi: 10.1038/nrd.2017.162. Epub 2017 Sep 22.
本文引用的文献
1
Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).托法替尼（CP-690,550）对固有和适应性免疫反应的调节。
J Immunol. 2011 Apr 1;186(7):4234-43. doi: 10.4049/jimmunol.1003668. Epub 2011 Mar 7.
2
Understanding latent tuberculosis: a moving target.理解潜伏性结核：一个动态的目标。
J Immunol. 2010 Jul 1;185(1):15-22. doi: 10.4049/jimmunol.0903856.
3
Penitentiary or penthouse condo: the tuberculous granuloma from the microbe's point of view.牢狱或顶层公寓：从微生物的角度看结核性肉芽肿。
Cell Microbiol. 2010 Mar;12(3):301-9. doi: 10.1111/j.1462-5822.2009.01424.x. Epub 2009 Dec 21.
4
Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.在潜伏性结核感染小鼠模型中采用利福喷汀每日给药的短程疗法。
Am J Respir Crit Care Med. 2009 Dec 1;180(11):1151-7. doi: 10.1164/rccm.200905-0795OC. Epub 2009 Sep 3.
5
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.一种JAK抑制剂在活动性类风湿关节炎患者中的安全性和有效性：CP-690,550三个剂量水平与安慰剂对照的双盲IIa期试验结果
Arthritis Rheum. 2009 Jul;60(7):1895-905. doi: 10.1002/art.24567.
6
Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis.一项双盲、安慰剂对照、剂量递增研究，旨在评估CP-690,550对银屑病患者的药理作用。
J Invest Dermatol. 2009 Sep;129(9):2299-302. doi: 10.1038/jid.2009.25. Epub 2009 Feb 19.
7
Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics.CP-690 550在稳定肾移植受者中的1期剂量递增研究：安全性、耐受性、对淋巴细胞亚群的影响及药代动力学的初步结果
Am J Transplant. 2008 Aug;8(8):1711-8. doi: 10.1111/j.1600-6143.2008.02307.x. Epub 2008 Jun 28.
8
The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia.JAK-3抑制剂CP-690550在小鼠肺嗜酸性粒细胞增多症模型中是一种有效的抗炎剂。
Eur J Pharmacol. 2008 Mar 17;582(1-3):154-61. doi: 10.1016/j.ejphar.2007.12.024. Epub 2007 Dec 28.
9
Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease.综述文章：在抗肿瘤坏死因子-α治疗炎症性肠病期间将结核病风险降至最低
Aliment Pharmacol Ther. 2008 Jan 1;27(1):19-30. doi: 10.1111/j.1365-2036.2007.03553.x. Epub 2007 Oct 16.
10
Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG.用牛分枝杆菌卡介苗进行气溶胶免疫后小鼠的少菌型结核病
Infect Immun. 2004 Feb;72(2):1065-71. doi: 10.1128/IAI.72.2.1065-1071.2004.
Zotero 插件